Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30135
Hepatitis B Virus Infection among Egyptian Children Vaccinated during Infancy

Authors: Iman I. Salama, Samia M. Sami, Somaia I. Salama, Zeinab N. Said, Thanaa M. Rabah, Aida M. Abdel-Mohsin

Abstract:

This is a national community based project to evaluate effectiveness of HBV vaccination program in prevention of infection. HBV markers were tested in the sera of 3600 vaccinated children. Infected children were followed up for 1 year. Prevalence of HBV infection was 0.39 % (0.28% positive for anti-HBc, 0.03% positive for HBsAg and 0.08% positive for both). One year later, 50% of positive anti-HBc children turned negative with sustained positivity for positive HBsAg cases. HBV infection was significantly higher at age above 9 years (0.6%) compared to 0.2% at age 3-9 years and 0% at younger age (P<0.05). Logistic analysis revealed that predictors for HBV infection were history of blood transfusion, regular medical injection, and family history of either HBV infection or drug abuse (adjusted odds ratios 6.2, 5.6, 7.6 & 19.1 respectively). HBV vaccination program produced adequate protection. Adherence to infection control measures and safe blood transfusion are recommended.

Keywords: Children, Egypt, HBV Infection, HBV Vaccine.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1089471

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 2243

References:


[1] C. J. Chen, and H. I. Yang, "Natural history of chronic hepatitis B”, J Gastroenterol Hepatol., 26(4):628-38, Apr. 2011.
[2] J. J. Ott, G. A. Stevens, J. Groeger, and S. T. Wiersma, "Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity”, Vaccine: 30: 2212-2219, 2012.
[3] WHO, "Prevention & Control of Viral Hepatitis Infection: Framework for Global Action”, 2012. http://www.who.int/.
[4] WHO, "Vaccines and Biologicals. Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents”. DEPARTMENTWHO/V&B/01.31 http://www.who.int/vaccinesdocuments/, 2001.
[5] A. El-Zayadi, "Hepatitis B Virus Infection: "The Egyptian Situation”, Arab J Gastroentol., 8(3): 94-98, 2007.
[6] A. P. Jimenez, N. S. El-Din, M. El-Hoseiny, M. El-Daly, M. Abdel-Hamid, S. ElAidi, Y. Sultan, N. El-Sayed, M. K. Mohamed, and A. Fontanet, "Community transmission of hepatitis B virus in Egypt: results from a case-control study in Greater Cairo”, Int J Epidemiol., 38(3):757-65, 2009.
[7] World Health Organization (WHO), "Hepatitis B fact sheet No. 204.”, July 2013. Available at: http://www.who.int/mediacentre/factsheets/ fs204/en.
[8] A. R. Zanetti, P. Van Damme, and Daniel Shouval, "The global impact of vaccination against hepatitis B: A historical overview”, Vaccine, 26: 6266-6273, 2008.
[9] J. Poorolajal, M. Mahmoodi, R. Majdzadeh, S. Nasseri-Moghaddam, A. Haghdoost, and A. Fotouhi, "Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis”, Vaccine, 8; 28(3):623-31, Jan. 2010.
[10] M. A. van der Sande, P. Waight, M. Mendy, P. Rayco-Solon, P. Hutt, T. Fulford, C Doherty, S. J. McConkey, D. Jeffries, A. J. Hall, and H. C. Whittle, "Long-term protection against carriage of hepatitis B virus after infant vaccination”, J Infect Dis., 1;193(11):1528-35, Jun. 2006.
[11] M-H. Chang M-H, "Breakthrough infection in vaccinated children in Taiwan: surveillance for HBV mutant,” Antiviral Therapy, 15:463-469, 2010.
[12] M. E. Tosti, B. McMahon, M. van der Sande, H. Whittle, C-F. Jan,and Y. Poovorawan, "Viral hepatitis,” This issue of Viral Hepatitis reviews topics covered at the VHPB’s autumn meeting held on November 17-18, 2011 in Milan, Italy. Viral hepatitis, Vol. 20-2, July 2012.
[13] S. I. Fahmy and A. F. El-Sherbiny, "Determining simple parameters for social classifications for health research". The Bulletin of the High institute of Public Health; vol. XIII, 5: 95-103, 1983.
[14] WHO, Hepatitis B, WHO/CDS/CSR/mLYO/2002. 2:1–76. 2002.
[15] A. Zanetti, A. Parlato, L. Roman, M. G. Desole, G. Ferrera, F. Giurdanella, M. Zuliani, P. Richard, S. Thomas and A. Fiquet, "Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: An open-label, randomised trial in Italy,” Vaccine, 30: 5770– 5775, 2012.
[16] M. Mendy, I. Peterson, S. Hossin, T. Peto, M. L. Jobarteh, A. Jeng-Barry, M. Sidibeh, A. Jatta, S. E. Moore, A. J. Hall, and H. Whittle, "Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B vaccination in two Gambian villages: no need for a booster dose,” PLoS One, 8(3):e58029, 2013.
[17] F. El-Zanaty, and W. Ann, "Egypt Demographic and Health Survey 2003,” Cairo, Egypt Ministry of Health, El-Zanaty and Associates, and Macro International, 2003.
[18] F. El-Zanaty, and W. Ann, "Egypt Demographic and Health Survey 2008,” Cairo, Egypt Ministry of Health, El-Zanaty and Associates, and Macro International, 2009.
[19] I. H. el-Sawy, and O. N. Mohamed, "Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children,” East Mediterr Health J., 5: 922-932, 1999.
[20] H. Z. Shatat, A. M. Kotkat, and Z. I. Imam, "Follow-up study of the immunogenecity and efficiency of hepatitis B vaccine in Egyptian children,” J Med Res Inst., 21: 126-136, 2000.
[21] A. A. Reda, M. A. Arafa, A. A. Youssry, E. H. Wandan, M. Ab de Ati, and H. Daebees, "Epidemiologic evaluation of the immunity against hepatitis B in Alexandria, Egypt,” European Journal of Epidemiology, 18: 1007-1011, 2013.
[22] A. G. Soliman, M. S. Hassan, N. A. Makhlouf, Z. Mohamed, Z. Abd Elrhman, and K. A. Khalaf, "Screening for HBsAg among Vaccinated School Children in Upper Egypt,” J Am Sci., 9(7):404-406, 2013. (ISSN: 1545-1003). http://www.jofamericanscience.org.
[23] X. Li, Y. Zheng, A. Liau, B. Cai, D. Ye, F. Huang, X. Sheng, F. Ge, L. Xuan, S. Li, and J. Li et al., "Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological study,” BMC Public Health, 12:272, 2012. http://www.biomedcentral.com/1471-2458/12/272.
[24] M. W. Lai, T. Y. Lin, K. C. Tsao , C. G. Huang, M. J. Hsiao, K. H. Liang, and C. T. Yeh, "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination,” Gastroenterology, 143(2):400-7, Aug. 2012.
[25] F. H. Su, C. H. Bai, F. Y. Chu, Y. S. Lin, C. T. Su, and C. C. Yeh, "Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan,” Vaccine, 8; 30(27):4034-9, Jun. 2012.
[26] CDC, "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States,” Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1 Immunization of Infants, Children, and Adolescents. MMWR Morb Mortal Wkly Rep. 54(RR-16):1-23, 2005.
[27] Y. Poovorawan, V. Chongsrisawat, A. Theamboonlers, K. Srinivasa, Y. Hutagalung, H. L. Bock, and B. Hoet, "Long-term benefit of Hep B vaccination among children in Thailand with transient hepatitis B virus infection who were born to Hepatitis B surface antigen-positive mothers,” J Infect Dis., 200:33-8, 2009.
[28] K. M. Weinberger, T. Bauer, S. Bohm, and W. Jilg, "High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum,” Journal of General Virology, 81:1165–74, 2000.
[29] A. R. Zanetti, L. Romanò, C. Giambi, A. Pavan, V. Carnelli, G. Baitelli, G. Malchiodi, E. Valerio, A. Barale, M. A. Marchisio, D. Montù, A. E. Tozzi, and F. D’Ancona, "Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study,” Lancet Infect Dis., 10:755-61, 2010.
[30] B. J. McMahon, "The natural history of chronic hepatitis B virus infection”. Hepatology, 49: S45–S55, 2009.
[31] S. M. Alavian, B. Hajariazdeh, M. AhmadzadAsl, A. Kabir, and K. Bagheri Lankarani, "Hepatitis B virus infection in Iran: a systematic review,” Hepat Mon., 8:281–294, 2008.
[32] B Mao, MK Patel, K Hennessey, RJ Duncan, K Wannemuehler and SC Soeung, " Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia," Vaccine, 13;31(40):4459-64, 2013 Sep.
[33] A. P. Compri, I. Miura, G. Porta, M. F. Lemos, C. P. Saraceni, and R. C. Moreira, "Hepatitis B virus infection in children, adolescents, and their relatives: genotype distribution and precore and core gene mutations,” Revista da Sociedade Brasileira de Medicina Tropical, 45(3):301-304, may-jun., 2012.
[34] H. S. Barut , Ö. Günal , A. Göral , and I. Etikan,
[Prevalence of hepatitis B virus infection in children of HBsAg positive parents]. Mikrobiyol Bul., 45(2):359-65, Apr. 2011.
[35] L. G. Davis, D. J. Weber, and S. M. Lemon, "Horizontal transmission of hepatitis B Virus,” Lancet, 1:889-893, 1989.
[36] Y. Zheng, Y. Lu, Q. Ye, Y. Xia, Y. Zhou, Q. Yao, and S. Wei, "Should chronic hepatitis B mothers breastfeed? A meta-analysis,” BMC Public Health, 11:502, 2011.
[37] X. Chen, J. Chen, J. Wen, C. Xu, S. Zhang, Y. H. Zhou, and Y. Hu, "Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus,” PLoS One, 8(1):e55303, 2013.